United States 115th Congress Status: Passed Senate 1 R cosponsors

S 1052 — BENEFIT Act of 2017

Last action — Referred to the Subcommittee on Health.

  1. ✓
    Introduced
  2. ✓
    In Committee
  3. 3
    Passed Senate
  4. 4
    Passed House
  5. 5
    To Executive
  6. 6
    Enacted

This bill died with 115th Congress. It reached “Passed Senate” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.

This bill is no longer active — its legislative session has ended, so there are no live odds of enactment. It would have to be reintroduced in the current session to move again.

In plain language

The bill enhances patient-experience data use in drug approval processes.

The BENEFIT Act of 2017 mandates the integration of patient-experience data into the benefit-risk assessments for new drug approvals. This aims to improve the decision-making process by considering real patient feedback.

What this means for you
  • Healthcare: This means healthcare providers will have access to more patient-focused information during drug evaluations.

Summary

Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2017 or the BENEFIT Act of 2017 This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to consider patient-focused drug development data, such as patient preferences, patient-reported outcomes, and patient experiences, as part of the risk-benefit assessment of new drugs. Following approval of a drug, the FDA must include a description of how this information was considered in its statement of patient experience.

Bill Text

What changed in the latest version

5 added · 1 removed

Plain-language change summary

The text was updated to reflect that the bill S. 1052 has been referred to the House of Representatives and specifically to the Committee on Energy and Commerce. This change indicates the bill's progression in the legislative process from the Senate to the House.

→
Previous
Latest
1052 Engrossed in Senate (ES)] <DOC> 115th CONGRESS 1st Session S.
1052 Referred in House (RFH)] <DOC> 115th CONGRESS 1st Session S.
1052 _______________________________________________________________________ AN ACT To strengthen the use of patient-experience data within the benefit- risk framework for approval of new drugs.
1052 _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES August 4, 2017 Referred to the Committee on Energy and Commerce _______________________________________________________________________ AN ACT To strengthen the use of patient-experience data within the benefit- risk framework for approval of new drugs.
Secretary.
JULIE E.
115th CONGRESS 1st Session S.
ADAMS, Secretary.
1052 _______________________________________________________________________ AN ACT To strengthen the use of patient-experience data within the benefit- risk framework for approval of new drugs.
⬇ Download PDF
View plain text versions (3)

Action History

  1. Introduced in Senate

  2. Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

  3. Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent.(consideration: CR S4787-4788)

  4. Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent. (consideration: CR S4787-4788)

  5. Passed/agreed to in Senate: Passed Senate without amendment by Unanimous Consent.(text: CR S4788)

  6. Passed Senate without amendment by Unanimous Consent. (text: CR S4788)

  7. Message on Senate action sent to the House.

  8. Received in the House.

  9. Referred to the House Committee on Energy and Commerce.

  10. Referred to the Subcommittee on Health.

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 0 co-sponsors · 546 not signed on

Sponsors (1)

Co-sponsors (0)

None.

Not signed on (546)

546 members have not signed on to this bill.

Show all 546 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

healthcare health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does S 1052 do?
Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2017 or the BENEFIT Act of 2017 This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to consider patient-focused drug development data, such as patient preferences, patient-reported outcomes, and patient experiences, as part of the risk-benefit assessment of new drugs. Following approval of a drug, the FDA must include a description of how this information was considered in its statement of patient experience.
Who sponsors S 1052?
S 1052 is sponsored by Wicker, Roger F. (Republican).
What is the current status of S 1052?
This bill died with 115th Congress. It reached “Passed Senate” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
Where can I track S 1052?
Track S 1052 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on S 1052

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of S 1052

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →